Scheid M P, Goldstein G, Boyse E A
J Exp Med. 1978 Jun 1;147(6):1727-43. doi: 10.1084/jem.147.6.1727.
Results with a dual assay, for the induction of Thy-1+ T cells and of CR+ B cells from marker-negative precursors, confirm that thymopoietin is at present the only known selective inducer of prothymocytes. In contrast, various inducers, including ubiquitin, are active in both assays. Pharmacological evidence indicates that there are different cellular receptors for ubiquitin and thymopoietin. Prothymocytes and pro-CR+ B cells compose two distinct populations in bone marrow and spleen; their distribution in density gradients is different, and elimination of either population enriches the other proportionately. There are no noteworthy differences between induction of these two populations in regard to (a) kinetics, (b) dependence on temperature and protein synthesis, (c) activation by cAMP, and (d) inhibition by cGMP. The opposite inductive effects of cAMP and cGMP were corroborated by the use of pharmacological agents that raise or lower the levels of intracellular cyclic nucleotides. In contrast, a third induction assay, which monitors acquisition of the PC+ surface phenotype, indicates that this differentiative step, the last known for B cells, is initiated by cGMP and inhibited by cAMP. Induction of PC is also inhibited by thymopoietin, signifying that the inductive selectivity of thymopoietin is not due to restriction of its receptors to the T lineage cells. Rather it seems that receptors for thymopoietin occur also on PC-inducible and other B cells, although in this case geared biochemically to inhibition rather than expression of the succeeding gene program. This suggests a role for thymopoietin in the coordinated interregulation of lymphocyte classes, in addition to its better-known function as the thymic inducer of prothymocytes. Present data conform to a general scheme in which the cyclic nucleotides cAMP and cGMP, and agents that affect intracellular levels of these mediators, influence reciprocally the early and late (functional) phases of lymphocyte differentiation as a whole, while thymopoietin influences reciprocally the differentiation of the B and T classes of lymphocyte.
用双检测法检测标记阴性前体细胞诱导生成Thy-1+ T细胞和CR+ B细胞的结果证实,胸腺生成素是目前已知的唯一一种原胸腺细胞的选择性诱导剂。相比之下,包括泛素在内的多种诱导剂在两种检测中均有活性。药理学证据表明,泛素和胸腺生成素存在不同的细胞受体。原胸腺细胞和原CR+ B细胞在骨髓和脾脏中构成两个不同的群体;它们在密度梯度中的分布不同,去除其中任何一个群体都会相应地富集另一个群体。在以下方面,这两个群体的诱导没有显著差异:(a)动力学,(b)对温度和蛋白质合成的依赖性,(c)cAMP的激活作用,以及(d)cGMP的抑制作用。通过使用提高或降低细胞内环核苷酸水平的药理学试剂,证实了cAMP和cGMP相反的诱导作用。相比之下,第三种检测方法监测PC+表面表型的获得,结果表明,这一B细胞已知的最后分化步骤由cGMP启动并被cAMP抑制。胸腺生成素也能抑制PC的诱导,这表明胸腺生成素的诱导选择性并非由于其受体仅限于T系细胞。相反,胸腺生成素的受体似乎也存在于可诱导PC的细胞和其他B细胞上,尽管在这种情况下,其生化作用是抑制而非表达后续的基因程序。这表明胸腺生成素除了作为原胸腺细胞的胸腺诱导剂这一广为人知的功能外,在淋巴细胞类别的协调相互调节中也发挥作用。目前的数据符合一个总体模式,即环核苷酸cAMP和cGMP以及影响这些介质细胞内水平的试剂,相互影响淋巴细胞分化的早期和晚期(功能)阶段,而胸腺生成素则相互影响B细胞和T细胞类别的分化。